PUIG SANZ, LUIS FGS
lpuig@santpau.cat
Agut Busquets, Eugenia FGS
Altemir Vidal, Arcadi FGS
Bittencourt Moraes, Flavia IR
Bravo Gonzalez, Marina IR
Diaz-salazar Monreal, Maria IR
Flores Climente, Victor Adrian IR
Garces Gatnau, Joan Ramon FGS
Garcia Muret, Maria Pilar FGS
Gely Vila, Cristina IR
Iznardo Ruiz, Helena FGS
Lopez Ferrer, Anna FGS
Lopez Sanchez, Cristina FGS
Morales Munera, Caridad Elena FGS
Roe Crespo , Esther FGS
Ruiz Salas, Veronica FGS
Serra Baldrich, Esther FGS
Spertino , Jorge Luis FGS
Vilarrasa Rull, Eva FGS
Yelamos Pena, Oriol FGS
Amat-Samaranch V., Puig L. (2020) Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. EXPERT OPIN DRUG SAF, 19 (4), 423-432.
IF: 4,250
Armstrong A., Paul C., Puig L., Boehncke W.H., Freeman M., Torii H., Papp K., Griffiths C.E.M., Blauvelt A., Reich K., Gooderham M., Terui T., Renda L., Agada N., Xu W., Gallo G., Lebwohl M.G. (2020) Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. DERMATOLOGY THER, 10 (1), 133-150.
IF: 3,264
Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. (2020) Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA DERMATOL, 156 (3), 258-269.
IF: 10,282
Bronckers I.M.G.J., Paller A.S., West D.P., Lara-Corrales I., Tollefson M.M., Tom W.L., Hogeling M., Belazarian L., Zachariae C., Mahe E., Siegfried E., Blume-Peytavi U., Szalai Z., Vleugels R.A., Holland K., Murphy R., Puig L., Cordoro K.M., Lambert J., Alexopoulos A., Mrowietz U., Kievit W., Seyger M.M.B. (2020) A Comparison of Psoriasis Severity in Pediatric Patients Treated with Methotrexate vs Biologic Agents. JAMA DERMATOL, 156 (4), 384-392.
IF: 10,282
Cork M.J., Eckert L., Simpson E.L., Armstrong A., Barbarot S., Puig L., Girolomoni G., de Bruin-Weller M., Wollenberg A., Kataoka Y., Remitz A., Beissert S., Mastey V., Ardeleanu M., Chen Z., Gadkari A., Chao J. (2020) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J DERMATOL TREAT, 31 (6), 606-614.
IF: 3,359
Cubillos-Zapata C., Martinez-Garcia M.A., Diaz-Garcia E., Jaureguizar A., Campos-Rodriguez F., Sanchez-de-la-Torre M., Nagore E., Martorell-Calatayud A., Blasco L.H., Pastor E., Abad-Capa J., Montserrat J.M., Cabriada-Nuno V., Cano-Pumarega I., Corral-Penafiel J., Arias E., Mediano O., Somoza-Gonzalez M., Dalmau-Arias J., Almendros I., Farre R., Lopez-Collazo E., Gozal D., Garcia-Rio F. (2020) Obesity attenuates the effect of sleep apnea on active TGF-ß1 levels and tumor aggressiveness in patients with melanoma. SCI REP-UK, 10 (1), -.
IF: 4,379
Cubiro X., Rozas-Munoz E., Castel P., Roe Crespo E., Garcia-Melendo C., Puig L., Baselga E. (2020) Clinical and genetic evaluation of six children with diffuse capillary malformation and undergrowth. PEDIATR DERMATOL, 37 (5), 833-838.
IF: 1,588
de Bruin-Weller M., Gadkari A., Auziere S., Simpson E.L., Puig L., Barbarot S., Girolomoni G., Papp K., Pink A.E., Saba G., Werfel T., Eckert L. (2020) The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J EUR ACAD DERMATOL, 34 (5), 1026-1036.
IF: 6,166
del Alcazar E., Ferran M., Lopez-Ferrer A., Notario J., Vidal D., Riera J., Aparicio G., Gallardo F., Vilarrasa E., Alsina M., Puig L., Ferrandiz C., Carrascosa J.M. (2020) Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. J DERMATOL TREAT, 31 (3), 222-226.
IF: 3,359
del Alcazar E., Suarez-Perez J.A., Armesto S., Rivera R., Herrera-Acosta E., Herranz P., Martin I., Montesinos E., Hospital M., Vilarrasa E., Ferran M., Ruiz-Villaverde R., Sahuquillo-Torralba A., Ruiz-Genao D.P., Perez-Barrio S., Munoz C., Llamas M., Valenti F., Mitxelena M.J., Lopez-Ferrer A., Carretero G., Vidal D., Mollet J., Belinchon I., Carrascosa J.M. (2020) Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J EUR ACAD DERMATOL, 34 (12), 2821-2829.
IF: 6,166
Diels J., Thilakarathne P., Cameron C., McElligott S., Schubert A., Puig L. (2020) Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. BRIT J DERMATOL, 183 (2), 276-284.
IF: 9,302
Fernandez-de-Misa R., Hernandez-Machin B., Combalia A., Garcia Muret M.P., Servitje O., Muniesa C., Gallardo F., Pujol R.M., Marti R.M., Ortiz-Brugues A., Maronas-Jimenez L., Ortiz-Romero P.L., Blanch Rius L., Izu R., Roman C., Canueto J., Blanes M., Morillo M., Bastida J., Penate Y., Perez Gala S., Espinosa Lara P., Perez Gil A., Estrach T. (2020) Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J EUR ACAD DERMATOL, 34 (4), 762-768.
IF: 6,166
Fernandez-Figueras M.-T., Puig L. (2020) The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma: Epithelial-to-Mesenchymal Transition in Cutaneous SCC. CURR TREAT OPTION ON, 21 (6), -.
IF: 5,036
Gely C., Marin L., Gordillo J., Manosa M., Bertoletti F., Canete F., Gonzalez-Munoza C., Calafat M., Domenech E., Garcia-Planella E. (2020) Impact of pain associated with the subcutaneous administration of adalimumab Impacto del dolor asociado a la administración subcutánea de adalimumab. GASTROENT HEPAT-BARC, 43 (1), 9-13.
IF: 2,102
Gonzalez-Manso A., Agut-Busquet E., Romani J., Vilarrasa E., Bittencourt F., Mensa A., Canto E., Arostegui J.I., Vidal S., Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis (2020) DERMATOLOGY.
IF: 5,366
Iznardo H., Roe E., Puig L., Vikula M., Lopez-Sanchez C., Baselga E. (2020) Good response to pulsed dye laser in patients with capillary malformation-arteriovenous malformation syndrome (CM-AVM). PEDIATR DERMATOL, 37 (2), 342-344.
IF: 1,588
Iznardo H., Puig L. (2020) The safety of brodalumab for the treatment of psoriasis. EXPERT OPIN DRUG SAF, 19 (4), 365-372.
IF: 4,250
Iznardo H., Garcia-Melendo C., Yelamos O. (2020) Lentigo maligna: Clinical presentation and appropriate management. CLIN COSMET INV DERM, 13 (), 837-855.
IF: 2,489
Lopez-Sanchez C., Iznardo H., Mozos A., Flores-Climente V., Puig L. (2020) Purple ulcerated nodules in a middle-aged man. INT J DERMATOL, 59 (4), e96-e98.
IF: 2,736
Lopez-Sanchez C., Puig L. (2020) Guselkumab in the treatment of moderate-to-severe plaque psoriasis. IMMUNOTHERAPY-UK, 12 (6), 355-371.
IF: 4,196
Marron S.E., Miranda-Sivelo A., Tomas-Aragones L., Rodriguez-Cerdeira C., Tribo-Boixaro M.J., Garcia-Bustinduy M., Gracia-Cazana T., Ros-Abarca S., Roe-Crespo E., Diaz-Diaz R.M., Brufau-Redondo C., Martinez-Gonzalez M.C., Guerra-Tapia A., Gonzalez-Guerra E., Puig L. (2020) Body dysmorphic disorder in patients with acne: a multicentre study. J EUR ACAD DERMATOL, 34 (2), 370-376.
IF: 6,166
Mir-Bonafe J.F., Rozas-Munoz E., Pedemonte-Sarrias E., Mir-Bonafe M., Mir-Bonafe J.M., Piquero-Casals J., Puig L. (2020) Psoriasis precipitated by timolol eye drops. A series of eight cases. AUSTRALAS J DERMATOL, 61 (1), e91-e93.
IF: 2,875
Misery L., Weisshaar E., Brenaut E., Evers A.W.M., Huet F., Stander S., Reich A., Berardesca E., Serra-Baldrich E., Wallengren J., Linder D., Fluhr J.W., Szepietowski J.C., Maibach H., Honari G., Le Gall-Ianotto C., Takamori K., Richters R. (2020) Pathophysiology and management of sensitive skin: position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI). J EUR ACAD DERMATOL, 34 (2), 222-229.
IF: 6,166
Nogueira M., Puig L., Torres T. (2020) JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. DRUGS, 80 (4), 341-352.
IF: 9,546
Pereira M.P., Ziehfreund S., Rueth M., Ewering T., Legat F.J., Lambert J., Elberling J., Misery L., Brenaut E., Papadavid E., Garcovich S., Evers A.W.M., Halvorsen J.A., Szepietowski J.C., Reich A., Goncalo M., Lvov A., Bobko S., Serra-Baldrich E., Wallengren J., Savk E., Leslie T., Stander S., Zink A., Google search trends for itch in Europe: a retrospective longitudinal study (2020) J EUR ACAD DERMATOL.
IF: 6,166
Pereira M.P., Hoffmann V., Weisshaar E., Wallengren J., Halvorsen J.A., Garcovich S., Misery L., Brenaut E., Savk E., Potekaev N., Lvov A., Bobko S., Szepietowski J.C., Reich A., Bozek A., Legat F.J., Metz M., Streit M., Serra-Baldrich E., Goncalo M., Storck M., Greiwe I., Nau T., Steinke S., Dugas M., Stander S., Zeidler C., Dalgard F., Elberling J., Forner C., Leslie T., Riepe C., Schneider G., Stander H. (2020) Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J EUR ACAD DERMATOL, 34 (10), 2373-2383.
IF: 6,166
Puig L., Lomaga M., Hollister K., Dutronc Y., Berggren L., Van De Kerkhof P. (2020) An analysis of patient-reported outcomes in ixora-s: Comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis. ACTA DERM-VENEREOL, 100 (19), 1-7.
IF: 4,437
Puig L., Carrascosa J.-M., Dauden E., Sulleiro S., Guisado C. (2020) Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J DERMATOL TREAT, 31 (4), 344-351.
IF: 3,359
Puig L., Tsai T.-F., Bhutani T., Uy J., Ramachandran P., Song M., You Y., Gooderham M., Lebwohl M. (2020) Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J EUR ACAD DERMATOL, 34 (8), 1744-1749.
IF: 6,166
Puig L., Lebwohl M., Bachelez H., Sobell J., Jacobson A.A. (2020) Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial. J AM ACAD DERMATOL, 82 (2), 352-359.
IF: 11,527
Puig L. (2020) The safety of ixekizumab in psoriasis drug therapy. EXPERT OPIN DRUG SAF, 19 (2), 117-130.
IF: 4,250
Reich K., Puig L., Szepietowski J.C., Paul C., Lacour J.P., Tsianakas A., Sieder C., Rissler M., Pournara E., Orsenigo R. (2020) Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. BRIT J DERMATOL, 182 (2), 304-315.
IF: 9,302
Reich K., Warren R.B., Iversen L., Puig L., Pau-Charles I., Igarashi A., Ohtsuki M., Falques M., Harmut M., Rozzo S., Lebwohl M.G., Cantrell W., Blauvelt A., Thaci D. (2020) Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. BRIT J DERMATOL, 182 (3), 605-617.
IF: 9,302
Rivera R., Velasco M., Vidal D., Carrascosa J.M., Dauden E., Vilarrasa E., Notario J., Ruiz-Villaverde R., Yanguas I., Garcia-Latasa F.J., Ferran M., Lazaro-Simo A., de la Cueva P., Salgado-Boquete L., Belinchon I. (2020) The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study. DERMATOL THER, 33 (6), -.
IF: 2,851
Rodriguez-Jimenez P., Jimenez Y.D., Reolid A., Sanmartin-Jimenez O., Garces J.R., Rodriguez-Prieto M.A., Medrano R.M., Vilarrasa E., de Eusebio-Murillo E., Redondo P., Ciudad-Blanco C., Morales-Gordillo V., Toll-Abello A., Artola-Igarza J.L., Pacheco M.L.A., Markixana I.A., Fernandez R.S., Rubio A.A., Vazquez-Veiga H., Florez-Menendez A., de la Cueva Dobao P., Botella-Estrada R., Garcia-Bracamonte B., Carnero-Gonzalez L., Ruiz-Salas V., Sanchez-Sambucety P., Lopez-Estebaranz J.L., Gil P., Barchino L., Arenal M.M., Ocerin-Guerra I., Hueso L., Seoane-Pose M.J., Gonzalez-Sixto B., Cano-Martinez N., Escutia-Munoz B., Ortiz-Romero P.L., Garcia-Doval I., Descalzo M.A. (2020) State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS). INT J DERMATOL, 59 (3), 321-325.
IF: 2,736
Romani J., Vilarrasa E., Martorell A., Fuertes I., Ciudad C., Molina-Leyva A. (2020) Ustekinumab with intravenous infusion: Results in hidradenitis suppurativa. DERMATOLOGY, 236 (1), 21-24.
IF: 5,366
Rozas Munoz E., Mir-Bonafe J.F., Mozos A., Szafranska J., Puig L. (2020) Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Answer. AM J DERMATOPATH, 42 (3), 218-219.
IF: 1,533
Rozas-Munoz E., Mir-Bonafe J.F., Mozos A., Szafranska J., Puig L. (2020) Asymptomatic Exophytic Plaques on the Penis of a Patient With HIV Infection: Challenge. AM J DERMATOPATH, 42 (3), e28-e29.
IF: 1,533
Rozas-Munoz E., Mir-Bonafe J.F., Mozos A., Planas-Ciudad S., Garcia-Muret M.P. (2020) A 70-Year-Old Man With Raspberry-Like Tumors on the Nipples: Challenge. AM J DERMATOPATH, 42 (9), e122-e123.
IF: 1,533
Rozas-Munoz E., Mir-Bonafe J.F., Mozos A., Planas-Ciudad S., Garcia-Muret M.P. (2020) A 70-Year Old Man With Raspberry-Like Tumors on the Nipples: Answer. AM J DERMATOPATH, 42 (9), 708-709.
IF: 1,533
Ruiz de Morales J.M.G., Puig L., Dauden E., Canete J.D., Pablos J.L., Martin A.O., Juanatey C.G., Adan A., Montalban X., Borruel N., Orti G., Holgado-Martin E., Garcia-Vidal C., Vizcaya-Morales C., Martin-Vazquez V., Gonzalez-Gay M.A. (2020) Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. AUTOIMMUN REV, 19 (1), -.
IF: 9,754
Sanz-Martinez M.T., Moga E., Sanchez Martinez M.A., Zamora Atenza C., Vidal S., Juarez C., Puig L. (2020) High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti–TNF-α Therapy. J INVEST DERMATOL, 140 (6), 1176-1183.
IF: 8,551
Serra E., Campo C., Novak Z., Majorek-Olechowska B., Pulka G., Garcia-Bea A., Labeaga L. (2020) Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study. J DERMATOL TREAT, 31 (3), 270-278.
IF: 3,359
Torres T., Puig L. (2020) Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. AM J CLIN DERMATOL, 21 (3), 307-311.
IF: 7,403
Zouboulis C.C., Hansen H., Caposiena Caro R.D., Damiani G., Delorme I., Pascual J.C., Reguiai Z., Trigoni A., Vilarrasa E., Roldan F.A. (2020) Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/Acne inversa. DERMATOLOGY, 236 (1), 25-30.
IF: 5,366